Pre Exposure Prophylaxis News and Research

RSS

Research highlights an increase in informal use of doxyPEP/PrEP among key populations in the Netherlands

New research analyzing an online survey of 1,633 respondents found 15% recent use of doxycycline post- and pre-exposure prophylaxis (doxyPEP/PrEP) among men who have sex with men (MSM), transgender and gender diverse people in the Netherlands according to a recent study published by Eurosurveillance.

4 Jul 2025

Twice-yearly injection could transform HIV prevention efforts

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A once-daily pill named PrEP, or pre-exposure prophylaxis, has been a stalwart for HIV prevention-but only if people take it consistently and can routinely access a pharmacy.

3 Jul 2025

Study finds sharp rise in HIV prevention medication use among American youth

Eight times more American young adults now take medication to protect them from HIV than a decade ago, a new study finds.

23 May 2025

Older adults in sub-Saharan Africa face growing HIV epidemic

Prevention and treatment campaigns are not adequately targeting the particular needs of the 50+ years age group.

15 May 2025

Long-acting HIV drug emerges from decades of research and advocacy

In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.

8 May 2025

Clinical trial underway to assess effectiveness and safety of potential Long Covid treatment

A clinical trial is underway to assess the effectiveness and safety of sipavibart, AstraZeneca's long-acting monoclonal antibody designed to provide protection against Covid-19, as a potential treatment for Long Covid, the Nova Southeastern University (NSU) and the Schmidt Initiative for Long Covid (SILC) announced today.

1 May 2025

Legal challenge puts ACA’s preventive health services in jeopardy

A study by the Stanford Prevention Policy Modeling Lab (PPML) finds that almost 30% of privately insured individuals in the United States, or nearly 40 million people, use at least one of the free preventive health services guaranteed under the Affordable Care Act (ACA).

17 Apr 2025

Gender affirming hormone therapy reduces HIV risk for transgender people

Transgender people receiving gender-affirming hormone therapy have a 37% lower chance of acquiring HIV, and for people living with HIV, hormone therapy appears to offer a 44% lower chance of the virus remaining detectable in blood, according to a University of Michigan study.

27 Mar 2025

Study reveals an integrated care model for improving outcomes among people who inject drugs

Researchers from the HIV Prevention Trials Network (HPTN) presented results from the HPTN 094 ("INTEGRA") study at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

12 Mar 2025

Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP).

From Sino Biological Inc. 12 Mar 2025

HIV drug access remains a major challenge despite promising trial results

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these drugs to those who need it most will be critical, says Beatriz Grinsztejn, president of the International AIDS Society.

10 Jan 2025

Early results of doxy PEP rollout show mixed impact on STIs

As health care services begin offering doxycycline to prevent bacterial sexually transmitted infections (STIs), real-world evidence demonstrates that the postexposure strategy, called doxy PEP, is reducing the rate of syphilis and chlamydia, but has had little to no effect on gonorrhea and needs close monitoring for signals of antibiotic resistance.

6 Jan 2025

IAS-USA releases updated HIV treatment and prevention guidelines

On the occasion of World AIDS Day on 1 December 2024, the International Antiviral (formerly AIDS) Society-USA (IAS-USA) has published new international guidelines for the treatment and prevention of HIV.

15 Dec 2024

Herpes infections affect 846 million people worldwide

Around 846 million people aged between 15 and 49 are living with genital herpes infections – more than 1 in 5 of this age-group globally – according to new estimates released today.

11 Dec 2024

New HIV prevention injection offers 96% protection

For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including attending doctor's visits every three months and – most importantly – consistency.

27 Nov 2024

Research suggests no need for yellow fever vaccine booster after initial dose

Research shows a single yellow fever vaccine provides lifelong immunity, with breakthrough infections being rare, supporting WHO guidelines on vaccination.

11 Nov 2024

Affordability and supply remain critical to the success of long-lasting HIV drug

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has proven highly effective in human trials, say global health specialists.

21 Oct 2024

Sweden exceeds UNAIDS HIV goals but faces new challenges

Sweden has surpassed the UNAIDS 95-95-95 targets, with reduced HIV incidence and a steady increase in diagnosed and treated cases. However, challenges remain, especially among migrant populations and recent arrivals.

20 Oct 2024

Exclusion of indigenous voices hinders HIV progress in Latin America

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without access to life-saving medicines and prevention tools.

18 Oct 2024

Integrated HIV prevention strategy increases PrEP adherence among transgender women

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and feasibility of an integrated multicomponent strategy to enhance daily oral HIV pre-exposure prophylaxis (PrEP) uptake and adherence among transgender women in a randomized immediate versus deferred design.

12 Oct 2024